Thrombocytosis and STAT5 Activation in Chronic Myelogenous Leukemia Are Not Associated With JAK2 V617F or Calreticulin Mutations

被引：0
|
作者：
Turakhia, Samir [1 ]
Murugesan, Gurunathan [1 ]
Cotta, Claudiu [1 ]
Theil, Karl [1 ]
机构：
[1] Cleveland Clin, Cleveland, OH 44106 USA
来源：
LABORATORY INVESTIGATION | 2015年 / 95卷
关键词：
D O I：
暂无
中图分类号：
R-3 [医学研究方法]; R3 [基础医学];
学科分类号：
1001 ;
摘要：
1519
引用
收藏
页码：382A / 382A
页数：1
相关论文
共 50 条
  • [21] Simultaneous detection of JAK2 V617F mutation and Bcr-Abl translocation in a patient with chronic myelogenous leukemia
    de Mello Conchon, Monika Ribeiro
    Costa, Juliana Lima
    Yoshinaga Novaes, Mafalda Megumi
    Dorlhiac-Llacer, Pedro Enrique
    Fischer Chamone, Dalton de Alencar
    Bendit, Israel
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2008, 88 (02) : 243 - 245
  • [22] Simultaneous detection of JAK2 V617F mutation and Bcr-Abl translocation in a patient with chronic myelogenous leukemia
    Monika Ribeiro Mello de Conchon
    Juliana Lima Costa
    Mafalda Megumi Yoshinaga Novaes
    Pedro Enrique Dorlhiac-Llacer
    Dalton de Alencar Fischer Chamone
    Israel Bendit
    International Journal of Hematology, 2008, 88 : 243 - 245
  • [23] JAK2 V617F is associated with 5q-syndrome in Chinese
    Wong, K.
    Wong, W.
    Siu, L.
    Lau, T.
    Chan, N.
    CHROMOSOME RESEARCH, 2009, 17 : 114 - 114
  • [24] The JAK2 V617F mutation in de novo acute myelogenous leukemias
    Lee, JW
    Kim, YG
    Soung, YH
    Han, KJ
    Kim, SY
    Rhim, HS
    Min, WS
    Nam, SW
    Park, WS
    Lee, JY
    Yoo, NJ
    Lee, SH
    ONCOGENE, 2006, 25 (09) : 1434 - 1436
  • [25] JAK2 V617f in chronic myeloid leukemia: driving force or passive bystander?
    Tarantini, Francesco
    Cumbo, Cosimo
    Zagaria, Antonella
    Parciante, Elisa
    Anelli, Luisa
    Coccaro, Nicoletta
    Tota, Giuseppina
    Minervini, Crescenzio Francesco
    Redavid, Immacolata
    Rossi, Antonella Russo
    Conserva, Maria Rosa
    Specchia, Giorgina
    Musto, Pellegrino
    Albano, Francesco
    HEMATOLOGY, 2022, 27 (01) : 842 - 846
  • [26] V617F mutation in JAK2 is associated idiopathic myelofibrosis
    Campbell, PJ
    Griesshammer, M
    Döhner, K
    Döhner, H
    Kusec, R
    Hasselbalch, HC
    Larsen, TS
    Pallisgaard, N
    Giraudier, S
    Le Bousse-Kerdilès, MC
    Desterke, C
    Guerton, B
    Dupriez, B
    Bordessoule, D
    Fenaux, P
    Kiladjian, JJ
    Viallard, JF
    Brière, J
    Harrison, CN
    Green, AR
    Reilly, JT
    BLOOD, 2006, 107 (05) : 2098 - 2100
  • [27] The JAK2 V617F mutation in de novo acute myelogenous leukemias
    J W Lee
    Y G Kim
    Y H Soung
    K J Han,
    S Y Kim
    H S Rhim
    W S Min
    S W Nam
    W S Park
    J Y Lee
    N J Yoo
    S H Lee
    Oncogene, 2006, 25 : 1434 - 1436
  • [28] Effects of a novel, selective Jak2 inhibitor, AZ60, on STAT5 signaling and cellular growth in Jak2 V617F cell lines
    Gozgit, Joseph M.
    Bebernitz, Geraldine A.
    Patil, Pankaj
    Ye, Minwei
    Wu, Jiaquan
    Ioannidis, Stephanos
    Davies, Audrey
    Wang, Tao
    Huszar, Dennis
    Zinda, Michael
    BLOOD, 2007, 110 (11) : 1039A - 1039A
  • [29] Detection and interpretation of low level JAK2 V617F mutations
    Bryon, Jane
    Akiki, S.
    Griffiths, M.
    JOURNAL OF MEDICAL GENETICS, 2012, 49 : S46 - S46
  • [30] JAK2 mutations (V617F and exon 12) in children with erythrocytosis
    Randi, M. L.
    Scapin, M.
    Pacquola, E.
    Duner, E.
    Scandellari, R.
    Bonato, S.
    Putti, M. C.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2007, 92 : 88 - 88
12345